论文部分内容阅读
目的观察左卡尼汀对促红细胞生成素治疗肾性贫血疗效的影响。方法将50例尿毒症血液透析患者随机分成治疗组和对照组,两组患者均于血液透析后皮下注射促红细胞生成素,剂量为每周100～150U/kg,待血细胞比容(Hct)上升至30%时后减量。同时治疗组每次血液透析后静脉注射左卡尼汀20～50mg/(kg.次),疗程12周。结果治疗组的血红蛋白(Hb)、血细胞比容水平显著高于对照组(P<0.01)。治疗组于治疗后第12周促红细胞生成素用量较治疗前明显减少,而对照组促红细胞生成素用量无明显改变。而两组血压升高发生率差异无统计学意义(P=0.182)。结论左卡尼汀能减少促红细胞生成素的用量及提高其疗效,纠正肾性贫血。
Objective To observe the effect of levocarnitine on the therapeutic effect of erythropoietin on renal anemia. Methods 50 cases of hemodialysis patients with uremia were randomly divided into treatment group and control group. Both groups received subcutaneous injection of erythropoietin after hemodialysis at a dose of 100-150 U / kg per week until the hematocrit (Hct) increased To 30% after the reduction. At the same time, the treatment group was given L-carnitine 20 ~ 50mg / (kg) intravenously after hemodialysis for 12 weeks. Results Hemoglobin (Hb) and hematocrit in the treatment group were significantly higher than those in the control group (P <0.01). In the 12th week after treatment, the dosage of erythropoietin in the treatment group was significantly decreased compared with that before treatment, while the dosage of erythropoietin in the control group did not change significantly. There was no significant difference in the incidence of blood pressure between the two groups (P = 0.182). Conclusion L-carnitine can reduce the dosage of erythropoietin and improve its curative effect, correct renal anemia.